Complications of adult-onset Still’s disease and their management

References

• Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30(2):121–133.
   PubMed Web of Science ®Google Scholar
• Adult-Onset FB. Still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773–792.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13(7):708–722.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015 Feb;61(12):53–62.
   PubMedGoogle Scholar
• Maria ATJ, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014 Nov;13(11):1149–1159.
   PubMed Web of Science ®Google Scholar
• Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adult-onset Still’s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016 Aug;169:8–13.
   PubMed Web of Science ®Google Scholar
• Uppal SS, Al-Mutairi M, Hayat S, et al. Ten years of clinical experience with adult onset Still’s disease: is the outcome improving? Clin Rheumatol. 2007;26:1055–1060.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–136.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset Stil disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91–99.
   PubMed Web of Science ®Google Scholar
• Priori R, Colafrancesco S, Picarelli G, et al. Adult-onset Still’s disease: not always so good. Clin Exp Rheumatol. 2012 Jan-Feb;30(1):142. author reply 143. Epub 2012 Mar 7.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kavadath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33(3):305–314.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014 Apr 26;383(9927):1503–1516. Epub 2013 Nov 27.
   PubMed Web of Science ®Google Scholar
• Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int. 2012;32:1291–1298.
   PubMed Web of Science ®Google Scholar
• Colina M, Zucchini W, Ciancio G, et al. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum. 2011 Oct;41(2):279–285.
   PubMed Web of Science ®Google Scholar
• Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset still’s disease. Arthritis Rheum. 2010 Aug;62(8):2530–2535.
   PubMedGoogle Scholar
• Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016 Dec;14(1):194.
   PubMed Web of Science ®Google Scholar
• Masui-Ito A, Okamoto R, Ikejiri K, et al. Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease: case report and review of literature. Medicine (Baltimore). 2017;96(29):e7596.
   PubMed Web of Science ®Google Scholar
• Singh S, Samant R, Joshi VR. Adult onset Still’s disease: a study of 14 cases. Clin Rheumatol. 2008 Jan;27(1):35–39. Epub 2007 Aug 15.
   PubMed Web of Science ®Google Scholar
• Fukaya S, Yasuda S, Hashimoto T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford). 2008 Nov;47(11):1686–1691. Epub 2008 Sep 9.
   PubMed Web of Science ®Google Scholar
• Arlet JB, Le TH, Marinho A, et al. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006 Dec;65(12):1596–1601. Epub 2006 Mar 15.
   PubMed Web of Science ®Google Scholar
• Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003 Oct 15;49(5):633–639.
   PubMedGoogle Scholar
• Hot A, Toh ML, Coppéré B, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore). 2010 Jan;89(1):37–46.
   PubMed Web of Science ®Google Scholar
• Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133–1138. PubMed PMID: 17343315. Epub 2007/03/09.
   PubMed Web of Science ®Google Scholar
• Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(3):965–971.
   PubMed Web of Science ®Google Scholar
• Junge G, Mason J, Feist E. Adult onset Still’s disease—the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017 Oct;47(2):295–302. Epub 2017 Jun 23.
   PubMed Web of Science ®Google Scholar
• Banse C, Vittecoq O, Benhamou Y, et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still’s disease. Joint Bone Spine. 2013 Dec;80(6):653–655. Epub 2013 Jun 7.
   PubMed Web of Science ®Google Scholar
• Cifaldi L, Prencipe G, Caiello I. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015 Nov;67(11):3037–3046.
   PubMed Web of Science ®Google Scholar
• Weiss ES, Girard-Guyonvarc’h C, Holzinger D, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018 Jan 11. DOI:10.1182/blood-2017-12-820852 Epub ahead of print.
   Web of Science ®Google Scholar
• Girard-Guyonvarc’h C, Palomo J, Martin P, et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood. 2018 Jan 2. DOI:10.1182/blood-2017-06-789552 Epub ahead of print.
   Web of Science ®Google Scholar
• Lieben L. Autoinflammatory diseases: free IL-18 causes macrophage activation syndrome. Nat Rev Rheumatol. 2018 Feb 1. DOI:10.1038/nrrheum.2018.11 Epub ahead of print
   Google Scholar
• Deroux A, Andry F, Bouillet L. [Macrophage activation syndrome secondary to tocilizumab: myth or reality?]. [Article in French]Rev Med Interne. 2016 Aug;37(8):564–566. Epub 2016 Mar 9.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015 Apr;42(4):712–722. Epub 2015 Feb 15.
   PubMed Web of Science ®Google Scholar
• Agnihotri A, Ruff A, Gotterer L, et al. Adult onset Still’s disease associated with mycoplasma pneumoniae infection and hemophagocytic lymphohistiocytosis. Case Rep Med. 2016;2016:2071815. Epub 2016 Oct 26.
   PubMedGoogle Scholar
• Prendki V, Stirnemann J, Lemoine M, et al. Prevalence and clinical signifi cance of Küpff er cell hyperplasia with hemophagocytosis in liver biopsies. Am J Surg Pathol. 2011;35:337–345.
   PubMed Web of Science ®Google Scholar
• Gupta A, Weitzman S, Abdelhaleem M. The role of hemophagocytosis in bone marrow aspirates in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50:192–194.
   PubMed Web of Science ®Google Scholar
• Emmenegger U, Schaer DJ, Larroche C, et al. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly. 2005;135:299–314.
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604.
   PubMed Web of Science ®Google Scholar
• Fardet L, Coppo P, Kettaneh A, et al. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum. 2008;58:1521–1527.
   PubMed Web of Science ®Google Scholar
• Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol. 1997;66:135–151.
   PubMed Web of Science ®Google Scholar
• Wong KF, Chan JK. Reactive hemophagocytic syndrome: a clinicopathologic study of 40 patients in an oriental population. Am J Med. 1992;93:177–180.
   PubMed Web of Science ®Google Scholar
• Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014 Sep;66(9):2613–2620.
   PubMed Web of Science ®Google Scholar
• Hejblum G, Lambotte O, Galicier L, et al. A web-based delphi study for eliciting helpful criteria in the positive diagnosis of hemophagocytic syndrome in adult patients. PLoS One. 2014 Apr 7;9(4):e94024. eCollection 2014.
   PubMed Web of Science ®Google Scholar
• Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118:4041–4052.
   PubMed Web of Science ®Google Scholar
• Zhuang JL, Jiang QW, Xu Y, et al. Recombinant activated factor VII in hemophagocytic lymphohistiocytosis with disseminated intravascular coagulation. Chin Med J (Engl). 2011;124:3189–3191.
   PubMed Web of Science ®Google Scholar
• Celkan T, Alhaj S, Civilibal M, et al. Control of bleeding associated with hemophagocytic syndrome in children: an audit of the clinical use of recombinant activated factor VII. Pediatr Hematol Oncol. 2007;24:117–121.
   PubMed Web of Science ®Google Scholar
• Wang S, Degar BA, Zieske A, et al. Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia. Am J Hematol. 2004;77:391–396.
   PubMed Web of Science ®Google Scholar
• Quesnel B, Catteau B, Aznar V, et al. Successful treatment of juvenile rheumatoid arthritis associated haemophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF. Br J Haematol. 1997;97:508–510.
   PubMed Web of Science ®Google Scholar
• Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17(1):23–27. PubMed PMID: 21169853. Epub 2010/ 12/21.
   PubMed Web of Science ®Google Scholar
• Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4(11):615–620. PubMed PMID: 18825135. Epub 2008/10/01.
   PubMedGoogle Scholar
• Pamuk ON, Pamuk GE, Usta U, et al. Hemophagocytic syndrome in one patient with adult-onset still’s disease. Presentation with febrile neutropenia. Clin Rheumatol. 2007;26(5):797–800. PubMed PMID: 16550302. Epub 2006/ 03/22.
   PubMedGoogle Scholar
• Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38(1):180–181. PubMed PMID: 21196588. Epub 2011/ 01/05.
   PubMed Web of Science ®Google Scholar
• Parisi F, Paglionico A, Varriano V, et al. Refractory adult-onset still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8 mg/kg/d) of anakinra. Medicine (Baltimore). 2017 Jun;96(24):e6656.
   PubMed Web of Science ®Google Scholar
• Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345–2357.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369.
   PubMed Web of Science ®Google Scholar
• Watanabe E, Sugawara H, Yamashita T, et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still’s disease: a case-based review. Case Rep Med. 2016;2016:5656320. Epub 2016 Sep 5.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Février J, Nicolle A, et al. Tocilizumab in the treatment of the adult-onset still’s disease: current clinical evidence. Clin Rheumatol. 2013 Jan;32(1):141–147. Epub 2012 Oct 30.
   PubMed Web of Science ®Google Scholar
• Komiya Y, Takenaka K, Nagasaka K. Successful treatment of glucocorticoid and cyclosporine refractory adult-onset Still’s disease complicated with hemophagocytic syndrome with plasma exchange therapy and tocilizumab: a case report. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(6):478–483.
   PubMedGoogle Scholar
• Savage E, Wazir T, Drake M, et al. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still’s disease successfully treated with tocilizumab. Rheumatology (Oxford). 2014 Jul;7(53):1352–1353. Epub 2014 Mar 7.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Ito S, Murasawa A, et al. Two cases of adult-onset still’s disease treated with tocilizumab that achieved tocilizumab-free remission. Intern Med. 2015;54(20):2675–2679. Epub 2015 Oct 15.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012 May;58(2):287–294. Epub 2012 Mar 6.
   PubMed Web of Science ®Google Scholar
• Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still’s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7(4):252–256. PubMed PMID: 17039144. Epub 2006/ 10/14.
   PubMed Web of Science ®Google Scholar
• Moake JL. Hypercoagulable states. Adv Intern Med. 1990;35:235–247.
   PubMedGoogle Scholar
• Sakata N, Shimizu S, Hirano F, et al. Epidemiological study of adult‑onset Still’s disease using a Japanese administrative database. Rheumatol Int. 2016 Oct;36(10):1399–1405. Epub 2016 Aug 9.
   PubMed Web of Science ®Google Scholar
• Wouters JM, van De Putte LB. Adult-onset Still’s disease;clinical and laboratory features, treatment and progress of 45 cases. Q J Med. 1986 Nov;61(235):1055–1065.
   PubMedGoogle Scholar
• Mimura T, Shimodaira M, Kibata M, et al. Adult-onset Still’s disease with disseminated intravascular coagulation and hemophagocytic syndrome: a case report.BMC. Res Notes. 2014;7:940.
   PubMedGoogle Scholar
• Shinohara T, Hidaka T, Matsuki Y, et al. Calcinosis cutis and intestinal pseudoobstruction in a patient with adult onset Still’s disease associated with recurrent relapses of disordered coagulopathy. Intern Med. 1999 Jun;38(6):516–520.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Suwa A, Shinozawa T, et al. A case of adult onset still’s disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation. Nihon Rinsho Men’eki Gakkai kaishi=Japanese Journal of Clinical Immunology. 18(2):207–214. PubMed PMID: 7553055. Epub 1995/04/01.
   PubMedGoogle Scholar
• Yamashita S, Furukawa NE, Matsunaga T, et al. Extremely high serum ferritin: an instrumental marker of masquerading adult-onset Still’s disease with hemophagocytic syndrome. Am J Case Rep. 2017;Dec6(18):1296–1301.
   Google Scholar
• Colina M, Govoni M, Trotta F. Fatal myocarditis in adult-onset still disease with diffuse intravascular coagulation. Rheumatol Int. 2009 Sep;29(11):1355–1357. Epub 2008 Dec 2.
   PubMed Web of Science ®Google Scholar
• Namas R, Nannapaneni N, Venkatram M, et al. An unusual case of adult-onset Still’s disease with hemophagocytic syndrome, necrotic leukoencephalopathy and disseminated intravascular coagulation. Case Rep Rheumatol. 2014;2014:128623.
   PubMedGoogle Scholar
• Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset Still’s disease: A single center case series and comparison with literature. Semin Arthritis Rheum. 2016 Jun;45(6):711–716. Epub 2015 Nov 10.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Clin Rheumatol. 2009 Apr;28(4):485–487. Epub 2009 Jan 30.
   PubMed Web of Science ®Google Scholar
• Park JH, Bae JH, Choi YS, et al. Adult-onset Still’s disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A. J Korean Med Sci. 2004 Feb;19(1):137–141.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kato H. Macrophage activation syndrome associated with adult-onset Still’s disease successfully treated with anakinra. Case Rep Rheumatol. 2016;2016:3717392. Epub 2016 Oct 12.
   PubMedGoogle Scholar
• Kötter I, Wacker A, Koch S. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007 Dec;37(3):189–197. Epub 2007 Jun 20.
   PubMed Web of Science ®Google Scholar
• Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100:710–713.
   PubMed Web of Science ®Google Scholar
• El Karoui K, Karras A, Lebrun G, et al. Thrombotic microangiopathy and purtscher-like retinopathy associated with adult-onset Still’s disease: a role for glomerular vascular endothelial growth factor? Arthritis Rheum. 2009 Nov 15;61(11):1609–1613.
   PubMedGoogle Scholar
• Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004 Jun 1;103(11):4043–4049. Epub 2004 Feb 24.
   PubMed Web of Science ®Google Scholar
• Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010 Oct;29(10):1191–1194. Epub 2010 Mar 12.
   PubMed Web of Science ®Google Scholar
• Masuyama A, Kobayashi H, Kobayashi Y, et al. A case of adult-onset Still’s disease complicated by thrombotic thrombocytopenic purpura with retinal microangiopathy and rapidly fatal cerebral edema. Mod Rheumatol. 2013 Mar;23(2):379–385. Epub 2012 May 24.
   PubMed Web of Science ®Google Scholar
• Khobragade AK, Chogle AR, Ram RP, et al. Reversible posterior leukoencephalopathy syndrome in a case of adult onset Still’s disease with concurrent thrombotic thrombocytopenic purpura: response to high dose immunoglobulin infusions.J. Assoc Physicians India. 2012;60:59–62.
   PubMedGoogle Scholar
• Rawal S, Einbinder Y, Rubin L, et al. Thrombotic microangiopathy in a patient with adult-onset still’s disease. Transfusion. 2014 Nov;54(11):2983–2987. Epub 2014 May 20.
   PubMed Web of Science ®Google Scholar
• Hirata S, Okamoto H, Ohta S, et al. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still’s disease. Rheumatology (Oxford). 2006;45:1046–1047.
   PubMed Web of Science ®Google Scholar
• Gopal M, Cohn CD, McEntire MR, et al. Thrombotic thrombocytopenic purpura and adult onset Still’s disease. Am J Med Sci. 2009;337:373–376.
   PubMed Web of Science ®Google Scholar
• Dino O, Provenzano G, Giannuoli E, et al. Fulminant hepatic failure in adult onset Still’s disease. J Rheumatol. 1996 Apr;23(4):784–785.
   PubMed Web of Science ®Google Scholar
• McFarlane M, Harth M, Wall WJ. Liver transplant in adult still’s disease. J Rheumatol. 1997 Oct;24(10):2038–2041.
   PubMed Web of Science ®Google Scholar
• Fujii K, Rokutanda R, Osugi Y, et al. Adult-onset still’s disease complicated by autoimmune hepatitis: successful treatment with infliximab. Intern Med. 2012;51(9):1125–1128. Epub 2012 Apr 29.
   PubMed Web of Science ®Google Scholar
• Liu LL, Feng ML, Wang LNJ, et al. A case report of successful treatment with plasma exchange for adult-onset Still’s disease with autoimmune hepatitis. Clin Apher. 2010;25(2):74–76.
   PubMed Web of Science ®Google Scholar
• Xia LX, Xiao T. An unusual case of autoimmune hepatitis in a patient with adult-onset Still’s disease. Clin Rheumatol. 2010 Jan;29(1):95–97. Epub 2009 May 8.
   PubMed Web of Science ®Google Scholar
• Gambichler T, Paech V, Rotterdam S, et al. Hepatitis B-assocciated adult-onset Still’s disease presenting with neutrophilic urticaria. Eur J Med Res. 2003 Dec 9;8(12):527–530.
   PubMed Web of Science ®Google Scholar
• Ben M’rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore). 2009 May;88(3):131–140.
   PubMed Web of Science ®Google Scholar
• Omagari K, Matsunaga Y, Yamashita H, et al. Successful treatment with cyclosporin in adult-onset Still disease manifesting as acute hepatitis with marked hyperferritinemia. Am J Med Sci. 2003 Sep;326(3):148–151.
   PubMed Web of Science ®Google Scholar
• Sahutoglu T, Kara E, Dogan IO, et al. Acute severe hepatitis and hemophagocytosis in adult onset Still’s disease. Arch Iran Med. 2015 Oct;18(10):724–728. 0151810/AIM.0014
   PubMed Web of Science ®Google Scholar
• Mylona E, Golfinopoulou S, Samarkos M, et al. Acute hepatitis in adult Still’s disease during corticosteroid treatment successfully treated with anakinra. Clin Rheumatol. 2008 May;27(5):659–661. Epub 2007 Dec 20.
   PubMed Web of Science ®Google Scholar
• Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011 Apr;21(2):215–218. Epub 2010 Oct 8.
   PubMed Web of Science ®Google Scholar
• Drepper M, Rubbia-Brandt L, Spahr L. Tocilizumab-induced acute liver injury in adult onset Still’s disease. Case Reports Hepatol. 2013;2013:964828. Epub 2013 Jul 15.
   PubMedGoogle Scholar
• Hintenberger R, Falkinger A, Danninger K, et al. Cardiovascular disease in patients with autoinflammatory syndromes. Rheumatol Int. 2018 Jan;38(1):37–50. Epub 2017 Nov 1.
   PubMed Web of Science ®Google Scholar
• Buss SJ, Wolf D, Mereles D, et al. A rare case of reversible constrictive pericarditis with severe pericardial thickening in a patient with adult onset Stil’s disease. Int J Cardiol. 2010 Oct 8;144(2):e23e25. Epub 2009 Jan 30.
   Web of Science ®Google Scholar
• Bilska A, Willnska E, Sztumowicz M, et al. Reccurent effusive pericarditis in the course of adult-onset still’s disease–case reports of two patients. Pneumonol Alergol Pol. 2011;79(3):215–221.
   PubMedGoogle Scholar
• Dall’Ara F, Frassi M, Tincani A, et al. A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need? Clin Rheumatol. 2016;35(8):2117–2123. . Epub 2016 Jan 12.
   PubMed Web of Science ®Google Scholar
• Kawaguchi H, Tsuboi H, Yagishita M, et al. A case of severe adult-onset Still’s disease with constrictive pericarditis and pleuritis that was successfully treated with tocilizumab in addition to corticosteroids and cyclosporin. A. Intern Med. 2017 Dec 21. DOI:10.2169/internalmedicine.9809-17 [ Epub ahead of print].
   Google Scholar
• Gerfaud-Valentin M, Sève P, Iwaz J, et al. Myocarditis in adult-onset still disease. Medicine (Baltimore). 2014;93(17):280–289.
   PubMed Web of Science ®Google Scholar
• Ertugrul BM, Uyar G, Ozturk B, et al. A rare presentation of endocarditis in adult-onset Still’s disease in diagnosis of fever of unknown origin. J Rheumatol. 2012 Jan;39(1):198–199.
   PubMed Web of Science ®Google Scholar
• Garcia-Porrua C, Gonzalez-Juanatey C, Gonzalez-Gay MA. Endocarditis in adult onset Still’s disease: a 12 month followup. J Rheumatol. 2001 Sep;28(9):2141–2142.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American college of cardiology foundation task force on expert consensus documents and the American heart association: developed in collaboration with the American college of chest physicians, American thoracic society, inc., and the pulmonary hypertension association. Circulation. 2009 Apr 28;119(16):2250–2294. Epub 2009 Mar 30.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46:903–975.
   PubMed Web of Science ®Google Scholar
• Huertas A, Perros F, Tu L, et al. Immune dysregulation and endothelialdysfunction in pulmonary arterial hypertension: a complex interplay. Circulation. 2014;129:1332–1340.
   PubMed Web of Science ®Google Scholar
• Campos M, Schiopu E. Pulmonary arterial hypertension in adult-onset still’s disease: rapid response to anakinra. Case Rep Rheumatol. 2012;2012:537613.
   PubMedGoogle Scholar
• Chen CH, Chen HA, Wang HP, et al. Pulmonary arterial hypertension in autoimmune diseases: an analysis of 19 cases from a medical center in northern Taiwan. J Microbiol Immunol Infect. 2006;39:162–168.
   PubMedGoogle Scholar
• de Siqueira M. Rodrigues R and Kormann APM. Adult-onset Still’s disease and pulmonary arterial hypertension. Respir Med CME. 2009;2:70–72.
   Google Scholar
• Guilleminault L, Laurent S, Foucher A, et al. Pulmonary arterial hypertension in adult onset Still’s disease: a case report of a severe complication. BMC Pulm Med. 2016 May 10;16(1):72.
   PubMedGoogle Scholar
• Kadavath S, Zapantis E, Zolty R, et al. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset still’s disease: targeting IL-6. Int J Rheum Dis. 2014;17:336–340.
   PubMed Web of Science ®Google Scholar
• Khattri S, Barland P. Pulmonary hypertension in a patient with adult-onset Still disease: a rare entity or an overlooked complication? J Muscoskel Med. 2011 Oct 10;28:388.
   Google Scholar
• Lowther GH, Chertoff J, Cope J, et al. Pulmonary arterial hypertension and acute respiratory distress syndrome in a patient with adult-onset Stills disease. Pulm Circ. 2017 Oct-Dec;7(4):797–802.
   PubMed Web of Science ®Google Scholar
• Mehta MV, Manson DK, Horn EM, et al. An atypical presentation of adult-onset Still’s disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature. Pulm Circ. 2016 Mar;6(1):136–142.
   PubMed Web of Science ®Google Scholar
• Mubashir E, Ahmed MM, Hayat S, et al. Pulmonary hypertension in a patient with adult-onset Stills disease. Clin Rheumatol. 2007;26:1359–1361.
   PubMed Web of Science ®Google Scholar
• Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, et al. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still’s disease. Clin Exp Rheumatol. 2013;31:657–658.
   PubMed Web of Science ®Google Scholar
• Thakare M, Habibi S, Agrawal S, et al. Pulmonary arterial hypertension complicating adult-onset Still’s disease. Clin Rheumatol. 2013;32:S1–2.
   PubMed Web of Science ®Google Scholar
• Weatherald J, Lategan J, Helmersen D. Pulmonary arterial hypertension secondary to adult-onset Still’s disease: response to cyclosporine and sildenafil over 15 years of follow-up. Respir Med Case Rep. 2016 Jun 20;19:27–30. eCollection 2016.
   PubMed Web of Science ®Google Scholar
• Zen A, Yamashita N, Ueda M, et al. [A case of adult Still’s disease with pulmonary hypertension]. Ryumachi. 1990;30:45–52.
   PubMedGoogle Scholar
• Robillard N, Wistaff R, Lamarre-Cliche M, et al. Still out of breath? J Med Cases. 2013;4:240–244.
   Google Scholar
• Gerfaud-Valentin M, Cottin V, Jamilloux Y, et al. Parenchymal lung involvement in adult-onset Still disease: a STROBE-compliant case series and literature review. Medicine (Baltimore). 2016 Jul;95(30):e4258.
   PubMed Web of Science ®Google Scholar
• Wu N, Li Q, Gu CX, et al. Paraneoplastic syndrome mimicking adult-onset Still’s disease caused by advanced lung cancer: a case report. BMC Cancer. 2011;11:487.
   PubMed Web of Science ®Google Scholar
• Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset Still’s disease: a single center case series and comparison with literature. Semin Arthritis Rheum. 2016 Jun;45(6):711–716. Epub 2015 Nov 10.
   PubMed Web of Science ®Google Scholar
• Mattiuzzo M, FornoM D, Branca B, et al. Bilateral empyema caused by adult-onset Still’s disease. Respir Int Rev Thorac Dis. 2001;68:88–90.
   Google Scholar
• Sari I, Birlik M, Binicier O, et al. A case of adult-onset Still’s disease complicated with diffuse alveolar hemorrhage. J Korean Med Sci. 2009;24:155–157.
   PubMed Web of Science ®Google Scholar
• Ben Ghorbel I, Khanfir M, Houman MH. Amyloidosis in adult onset still’s disease. Rev Med Interne. 2004;25:675–677.
   PubMed Web of Science ®Google Scholar
• Ishii T, Sasaki T, Muryoi T, et al. Systemic amyloidosis in a patient with adult onset Still’s disease. Intern Med. 1993 jan;32(1):50–52.
   PubMed Web of Science ®Google Scholar
• Oh YB, Bae SC, Jung JH, et al. Secondary renal amyloidosis in adult onset Still’s disease: case report and review of the literature. Korean J Intern Med. 2000;15:131–134.
   PubMedGoogle Scholar
• Rivera F, Gil CM, Gil MT, et al. Vascular renal AA amyloidosis in adult Still’s disease. Nephrol Dial Transplant. 1997;12:1714–1716.
   PubMed Web of Science ®Google Scholar
• Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010 Aug 25;2(46):46ra62.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–266.
   PubMed Web of Science ®Google Scholar
• Mitrovic S, Fautrel B. New markers for adult-onset Still’s disease. Joint Bone Spine. 2017 May 18; pii: S1297-319X(17):30102–1. DOI:10.1016/j.jbspin.2017.05.011 Epub ahead of print.
   Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31(11):2189–2198.
   PubMed Web of Science ®Google Scholar
• Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30(11):2422–2427.
   PubMed Web of Science ®Google Scholar
• Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018 Feb 22. DOI:10.1136/annrheumdis-2017-212608 Epub ahead of print.
   Web of Science ®Google Scholar
• Priori R, Barone F, Alessandri C, et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology (Oxford). 2011;50(4):776–780.
   PubMed Web of Science ®Google Scholar